GenMark Diagnostics Price Target Raised to $15.00 at Raymond James (GNMK)
Equities research analysts at Raymond James lifted their price target on shares of GenMark Diagnostics (NASDAQ:GNMK) to $15.00 in a research note issued to investors on Wednesday, American Banking News reports. Raymond James’ target price would indicate a potential upside of 22.55% from the company’s current price.
Separately, analysts at Canaccord Genuity cut their price target on shares of GenMark Diagnostics (NASDAQ:GNMK) from $18.00 to $14.00 in a research note to investors on Thursday, August 8th. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $14.67.
Shares of GenMark Diagnostics (NASDAQ:GNMK) traded down 0.74% on Wednesday, hitting $12.15. The stock had a trading volume of 73,592 shares. GenMark Diagnostics has a 52 week low of $7.55 and a 52 week high of $16.00. The stock has a 50-day moving average of $11.38 and a 200-day moving average of $12.24. The company’s market cap is $397.7 million.
GenMark Diagnostics (NASDAQ:GNMK) last released its earnings data on Wednesday, August 7th. The company reported ($0.25) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.26) by $0.01. The company had revenue of $5.20 million for the quarter, compared to the consensus estimate of $5.05 million. On average, analysts predict that GenMark Diagnostics will post $-0.91 earnings per share for the current fiscal year.
GenMark Diagnostics, Inc (NASDAQ:GNMK) is a molecular diagnostics company focused on developing and commercializing its eSensor detection technology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.